The Dedham Group’s Post

Few drugs have gripped the American public, like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace BioSpace article, The Dedham Group’s Manuel Jurado provides commentary on the connection between the GLP-1 and the insulin market. Check out the full article: https://ow.ly/fM0k50RRFa6 #GLP1 #Insulin #Biopharma #PharmaceuticalCompanies

Few drugs have gripped the American public, like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace BioSpace article, The Dedham Group’s Manuel Jurado provides commentary on the connection between the GLP-1 and the insulin market. Check out the full article: https://ow.ly/Uhfc50RRFhb #GLP1 #Insulin #Biopharma #PharmaceuticalCompanies

Few drugs have gripped the American public like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace article, I provide commentary on the connection between the GLP-1 and the insulin market. Check out the full article.. https://lnkd.in/eXKA8yEy

🔷When we think about inflation, we need to give credit to the pharmaceutical industry for displacing every other sector (hospital, ambulatory/physician, etc.,) as the fastest growing cost element of the US healthcare system....this year will not disappoint as a whopper of a year for upward cost pressure. 🔷And which drugs are the biggest contributors? Semaglutide was the top (GLP-1 - officially a T2 diabetes drug but often used for rapid weight loss) adalimumab (a.k.a. Humira and all it's biosimilar cousins) than apixaban (a.k.a. eloquis - an anticoagulant medication) #healthcare #inflation #drugcosts

The global Intravenous Antiepileptic Drug market was valued at US$ 452 million in 2023 and is anticipated to reach US$ 677 million by 2030 witnessing a CAGR of 4.8% during the forecast period 20242030. #EpilepsyTreatment #IntravenousAEDs #GlobalMarket #HospitalPharmacies #RetailPharmacies #OnlinePharmacies #DrugStores #HealthcareInnovation #PatientCare #MarketGrowth

Dapagliflozin, developed by Parand Darou pharmaceutical company as an SGLT2 inhibitor, is a treatment for individuals with type 2 diabetes. By blocking SGLT2 cotransporters responsible for glucose reabsorption in the kidneys, this medication enhances glucose excretion, leading to reduced blood glucose levels. However, the standout feature of dapagliflozin lies in its additional benefits for heart failure and kidney complications in diabetic patients. Specifically recommended for diabetic individuals with existing or at-risk cardiovascular issues, this drug also helps lower cardiovascular risks and is an integral part of their treatment regimen. Parand Darou #diabetes #pharmaceutical #medicine #api #pharma #paranddarou

Codeine Market Outlook 2024-2030 For Additional Information, Get a Sample Copy>>> https://lnkd.in/dswaUvzu The codeine market refers to the segment of the pharmaceutical industry that focuses on the production, distribution, and sale of codeine, an opioid medication used primarily to treat mild to moderate pain, coughing, and diarrhea. As a controlled substance, codeine is often formulated in combination with other medications like acetaminophen or ibuprofen and is available in both prescription and over-the-counter products in some regions. The market includes pharmaceutical companies, healthcare providers, and regulatory bodies, with demand driven by the need for effective pain management and cough suppression. However, it is also regulated due to the potential for misuse and addiction. #KeyPlayers::: Alcaliber (Spain), AUROBINDO PHARMA LTD (India), Endo Pharmaceuticals (United States), GSK (United Kingdom), Johnson & Johnson (United States), Lannett Company, Inc. (United States), Lupin (India), Mallinckrodt Pharmaceuticals (United States), Noramco™ (United States), Rhodes Pharmaceuticals (United States), Sanofi (France), Sun Pharmaceutical Sdn Bhd (India) #CodeineMarket #Codeine #Pharmaceuticals #Pharmaceuticalindustry #pharmaceuticalnews #htfmi #htf HTF Market Intelligence Consulting Pvt Ltd

We read that the pricing of life-saving pharmaceutical products such as #GLP-1 like #Ozempic and #Wegovy, along with #insulin, is once again under scrutiny. The focus is mostly on the manufacturing costs, using the marginal production cost argument. However, it's important to remember that these products are essential for patients suffering from diabetes and obesity. Companies such as #NovoNordisk understand the importance of ensuring access to these medications to all eligible patients. Let's hope that the focus shifts from mere production costs to funding additional researched in these fields, and to making these medications more affordable for those who need them.

Alembic Pharma gets USFDA nod to Diltiazem Hydrochloride ER Capsules to treat hypertension Drug maker Alembic Pharmaceuticals Limited has recently announced that it has received final approval from the United States Food and Drug Administration (US FDA) for the abbreviated new drug application (ANDA) Diltiazem Hydrochloride extended-release capsules of strengths 120 mg, 180 mg, and 240 mg. The approved ANDA is therapeutically equivalent to the reference listed drug, Dilacor XR Extended-Release Capsules (120 mg, 180 mg, and 240 mg), manufactured by Allergan Sales LLC, the company said in a statement. Diltiazem Hydrochloride Extended-Release Capsules USP are prescribed for hypertension management and can be used alone or alongside other antihypertensive drugs, like diuretics. Additionally, they are indicated for managing chronic stable angina. #AlembicPharma #USFDA #ANDA #DilacorXRExtendedReleaseCapsules #AllerganSalesLLC #DiltiazemHydrochlorideExtendedReleaseCapsules

The rising costs of healthcare, including medications, continue to be a significant concern for Americans. This issue is particularly pronounced in the pharmaceutical industry, where the development and production of advanced medications, including those like GLP-1 receptor agonists (GLP-1 RAs), contribute to higher expenses. The intersection of rising costs and the popularity of such medications presents complex challenges for both healthcare systems and individuals. This article provides some important points on the rise of these popular medications.